Eintrag weiter verarbeiten
Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy
Gespeichert in:
| Zeitschriftentitel: | Clinical Kidney Journal |
|---|---|
| Personen und Körperschaften: | , , , , , , , , |
| In: | Clinical Kidney Journal, 12, 2019, 4, S. 483-487 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Oxford University Press (OUP)
|
| Schlagwörter: |
| author_facet |
Bharati, Joyita Tiewsoh, Karalanglin Kumar, Ashwani Nada, Ritambhra Rathi, Manish Gupta, Krishan Lal Kohli, Harbir Singh Jha, Vivekananda Ramachandran, Raja Bharati, Joyita Tiewsoh, Karalanglin Kumar, Ashwani Nada, Ritambhra Rathi, Manish Gupta, Krishan Lal Kohli, Harbir Singh Jha, Vivekananda Ramachandran, Raja |
|---|---|
| author |
Bharati, Joyita Tiewsoh, Karalanglin Kumar, Ashwani Nada, Ritambhra Rathi, Manish Gupta, Krishan Lal Kohli, Harbir Singh Jha, Vivekananda Ramachandran, Raja |
| spellingShingle |
Bharati, Joyita Tiewsoh, Karalanglin Kumar, Ashwani Nada, Ritambhra Rathi, Manish Gupta, Krishan Lal Kohli, Harbir Singh Jha, Vivekananda Ramachandran, Raja Clinical Kidney Journal Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy Transplantation Nephrology |
| author_sort |
bharati, joyita |
| spelling |
Bharati, Joyita Tiewsoh, Karalanglin Kumar, Ashwani Nada, Ritambhra Rathi, Manish Gupta, Krishan Lal Kohli, Harbir Singh Jha, Vivekananda Ramachandran, Raja 2048-8505 2048-8513 Oxford University Press (OUP) Transplantation Nephrology http://dx.doi.org/10.1093/ckj/sfy127 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>C3 glomerulopathy (C3G) is a heterogeneous disease caused by alternative complement pathway abnormalities without any standardized treatment. An immunosuppressive agent, mycophenolate mofetil (MMF), has been recently shown to be useful in treating C3G, mainly in studies from the west. We report the clinical outcome of 17 Indian C3G patients treated with MMF with or without steroids.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>The clinical and histology details of the C3G patients treated with MMF for at least 6 months with a follow-up of at least 12 months were retrieved from the medical records of our center.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>The median serum creatinine and proteinuria at presentation were 0.8 mg/dL and 3.7 g/day, respectively, with the majority (88.2%) presenting as nephrotic syndrome. The mean dose of MMF was 1.65 (±0.56) g/day, and the median duration of MMF therapy was 18 months. Two-thirds (64%) of the patients responded to the treatment, with complete remission in 4 (23%) and partial remission in 7 (41%) (median time: 9 months). Three patients progressed to end-stage renal disease (ESRD) on follow-up. Of the three patients, one (33%) had an initial response in proteinuria to MMF but did not respond after a relapse and subsequently progressed to ESRD and two (67%) other patients were nonresponsive to MMF from the start of the therapy.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Despite a small sample size and lack of a control arm, this study describes the effectiveness of MMF in treating C3G patients from Asia and forms a basis for future randomized trials.</jats:p> </jats:sec> Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy Clinical Kidney Journal |
| doi_str_mv |
10.1093/ckj/sfy127 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9ja2ovc2Z5MTI3 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9ja2ovc2Z5MTI3 |
| institution |
DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 |
| imprint |
Oxford University Press (OUP), 2019 |
| imprint_str_mv |
Oxford University Press (OUP), 2019 |
| issn |
2048-8505 2048-8513 |
| issn_str_mv |
2048-8505 2048-8513 |
| language |
English |
| mega_collection |
Oxford University Press (OUP) (CrossRef) |
| match_str |
bharati2019usefulnessofmycophenolatemofetilinindianpatientswithc3glomerulopathy |
| publishDateSort |
2019 |
| publisher |
Oxford University Press (OUP) |
| recordtype |
ai |
| record_format |
ai |
| series |
Clinical Kidney Journal |
| source_id |
49 |
| title |
Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy |
| title_unstemmed |
Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy |
| title_full |
Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy |
| title_fullStr |
Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy |
| title_full_unstemmed |
Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy |
| title_short |
Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy |
| title_sort |
usefulness of mycophenolate mofetil in indian patients with c3 glomerulopathy |
| topic |
Transplantation Nephrology |
| url |
http://dx.doi.org/10.1093/ckj/sfy127 |
| publishDate |
2019 |
| physical |
483-487 |
| description |
<jats:title>Abstract</jats:title>
<jats:sec>
<jats:title>Background</jats:title>
<jats:p>C3 glomerulopathy (C3G) is a heterogeneous disease caused by alternative complement pathway abnormalities without any standardized treatment. An immunosuppressive agent, mycophenolate mofetil (MMF), has been recently shown to be useful in treating C3G, mainly in studies from the west. We report the clinical outcome of 17 Indian C3G patients treated with MMF with or without steroids.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Methods</jats:title>
<jats:p>The clinical and histology details of the C3G patients treated with MMF for at least 6 months with a follow-up of at least 12 months were retrieved from the medical records of our center.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results</jats:title>
<jats:p>The median serum creatinine and proteinuria at presentation were 0.8 mg/dL and 3.7 g/day, respectively, with the majority (88.2%) presenting as nephrotic syndrome. The mean dose of MMF was 1.65 (±0.56) g/day, and the median duration of MMF therapy was 18 months. Two-thirds (64%) of the patients responded to the treatment, with complete remission in 4 (23%) and partial remission in 7 (41%) (median time: 9 months). Three patients progressed to end-stage renal disease (ESRD) on follow-up. Of the three patients, one (33%) had an initial response in proteinuria to MMF but did not respond after a relapse and subsequently progressed to ESRD and two (67%) other patients were nonresponsive to MMF from the start of the therapy.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusion</jats:title>
<jats:p>Despite a small sample size and lack of a control arm, this study describes the effectiveness of MMF in treating C3G patients from Asia and forms a basis for future randomized trials.</jats:p>
</jats:sec> |
| container_issue |
4 |
| container_start_page |
483 |
| container_title |
Clinical Kidney Journal |
| container_volume |
12 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792334690212904966 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T14:32:40.08Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Usefulness+of+mycophenolate+mofetil+in+Indian+patients+with+C3+glomerulopathy&rft.date=2019-08-01&genre=article&issn=2048-8513&volume=12&issue=4&spage=483&epage=487&pages=483-487&jtitle=Clinical+Kidney+Journal&atitle=Usefulness+of+mycophenolate+mofetil+in+Indian+patients+with+C3+glomerulopathy&aulast=Ramachandran&aufirst=Raja&rft_id=info%3Adoi%2F10.1093%2Fckj%2Fsfy127&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792334690212904966 |
| author | Bharati, Joyita, Tiewsoh, Karalanglin, Kumar, Ashwani, Nada, Ritambhra, Rathi, Manish, Gupta, Krishan Lal, Kohli, Harbir Singh, Jha, Vivekananda, Ramachandran, Raja |
| author_facet | Bharati, Joyita, Tiewsoh, Karalanglin, Kumar, Ashwani, Nada, Ritambhra, Rathi, Manish, Gupta, Krishan Lal, Kohli, Harbir Singh, Jha, Vivekananda, Ramachandran, Raja, Bharati, Joyita, Tiewsoh, Karalanglin, Kumar, Ashwani, Nada, Ritambhra, Rathi, Manish, Gupta, Krishan Lal, Kohli, Harbir Singh, Jha, Vivekananda, Ramachandran, Raja |
| author_sort | bharati, joyita |
| container_issue | 4 |
| container_start_page | 483 |
| container_title | Clinical Kidney Journal |
| container_volume | 12 |
| description | <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>C3 glomerulopathy (C3G) is a heterogeneous disease caused by alternative complement pathway abnormalities without any standardized treatment. An immunosuppressive agent, mycophenolate mofetil (MMF), has been recently shown to be useful in treating C3G, mainly in studies from the west. We report the clinical outcome of 17 Indian C3G patients treated with MMF with or without steroids.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>The clinical and histology details of the C3G patients treated with MMF for at least 6 months with a follow-up of at least 12 months were retrieved from the medical records of our center.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>The median serum creatinine and proteinuria at presentation were 0.8 mg/dL and 3.7 g/day, respectively, with the majority (88.2%) presenting as nephrotic syndrome. The mean dose of MMF was 1.65 (±0.56) g/day, and the median duration of MMF therapy was 18 months. Two-thirds (64%) of the patients responded to the treatment, with complete remission in 4 (23%) and partial remission in 7 (41%) (median time: 9 months). Three patients progressed to end-stage renal disease (ESRD) on follow-up. Of the three patients, one (33%) had an initial response in proteinuria to MMF but did not respond after a relapse and subsequently progressed to ESRD and two (67%) other patients were nonresponsive to MMF from the start of the therapy.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Despite a small sample size and lack of a control arm, this study describes the effectiveness of MMF in treating C3G patients from Asia and forms a basis for future randomized trials.</jats:p> </jats:sec> |
| doi_str_mv | 10.1093/ckj/sfy127 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9ja2ovc2Z5MTI3 |
| imprint | Oxford University Press (OUP), 2019 |
| imprint_str_mv | Oxford University Press (OUP), 2019 |
| institution | DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4 |
| issn | 2048-8505, 2048-8513 |
| issn_str_mv | 2048-8505, 2048-8513 |
| language | English |
| last_indexed | 2024-03-01T14:32:40.08Z |
| match_str | bharati2019usefulnessofmycophenolatemofetilinindianpatientswithc3glomerulopathy |
| mega_collection | Oxford University Press (OUP) (CrossRef) |
| physical | 483-487 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | Oxford University Press (OUP) |
| record_format | ai |
| recordtype | ai |
| series | Clinical Kidney Journal |
| source_id | 49 |
| spelling | Bharati, Joyita Tiewsoh, Karalanglin Kumar, Ashwani Nada, Ritambhra Rathi, Manish Gupta, Krishan Lal Kohli, Harbir Singh Jha, Vivekananda Ramachandran, Raja 2048-8505 2048-8513 Oxford University Press (OUP) Transplantation Nephrology http://dx.doi.org/10.1093/ckj/sfy127 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>C3 glomerulopathy (C3G) is a heterogeneous disease caused by alternative complement pathway abnormalities without any standardized treatment. An immunosuppressive agent, mycophenolate mofetil (MMF), has been recently shown to be useful in treating C3G, mainly in studies from the west. We report the clinical outcome of 17 Indian C3G patients treated with MMF with or without steroids.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>The clinical and histology details of the C3G patients treated with MMF for at least 6 months with a follow-up of at least 12 months were retrieved from the medical records of our center.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>The median serum creatinine and proteinuria at presentation were 0.8 mg/dL and 3.7 g/day, respectively, with the majority (88.2%) presenting as nephrotic syndrome. The mean dose of MMF was 1.65 (±0.56) g/day, and the median duration of MMF therapy was 18 months. Two-thirds (64%) of the patients responded to the treatment, with complete remission in 4 (23%) and partial remission in 7 (41%) (median time: 9 months). Three patients progressed to end-stage renal disease (ESRD) on follow-up. Of the three patients, one (33%) had an initial response in proteinuria to MMF but did not respond after a relapse and subsequently progressed to ESRD and two (67%) other patients were nonresponsive to MMF from the start of the therapy.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Despite a small sample size and lack of a control arm, this study describes the effectiveness of MMF in treating C3G patients from Asia and forms a basis for future randomized trials.</jats:p> </jats:sec> Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy Clinical Kidney Journal |
| spellingShingle | Bharati, Joyita, Tiewsoh, Karalanglin, Kumar, Ashwani, Nada, Ritambhra, Rathi, Manish, Gupta, Krishan Lal, Kohli, Harbir Singh, Jha, Vivekananda, Ramachandran, Raja, Clinical Kidney Journal, Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy, Transplantation, Nephrology |
| title | Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy |
| title_full | Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy |
| title_fullStr | Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy |
| title_full_unstemmed | Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy |
| title_short | Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy |
| title_sort | usefulness of mycophenolate mofetil in indian patients with c3 glomerulopathy |
| title_unstemmed | Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy |
| topic | Transplantation, Nephrology |
| url | http://dx.doi.org/10.1093/ckj/sfy127 |